HC Wainwright Weighs in on Galectin Therapeutics Inc.’s Q1 2025 Earnings (NASDAQ:GALT)

Galectin Therapeutics Inc. (NASDAQ:GALT) – Research analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for Galectin Therapeutics in a research report issued to clients and investors on Friday, August 16th. HC Wainwright analyst E. Arce expects that the company will earn ($0.24) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $11.00 target price on the stock. The consensus estimate for Galectin Therapeutics’ current full-year earnings is ($0.66) per share. HC Wainwright also issued estimates for Galectin Therapeutics’ Q2 2025 earnings at ($0.27) EPS, Q3 2025 earnings at ($0.63) EPS, Q4 2025 earnings at ($0.53) EPS and FY2027 earnings at $1.29 EPS.

Galectin Therapeutics (NASDAQ:GALT) last released its quarterly earnings results on Tuesday, August 13th. The company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.04).

Separately, StockNews.com lowered Galectin Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, July 18th.

Galectin Therapeutics Trading Down 2.1 %

NASDAQ GALT opened at $2.30 on Monday. The firm has a market capitalization of $142.94 million, a P/E ratio of -3.11 and a beta of 0.63. The business has a fifty day simple moving average of $2.34 and a 200 day simple moving average of $2.55. Galectin Therapeutics has a 12 month low of $1.55 and a 12 month high of $4.27.

Institutional Investors Weigh In On Galectin Therapeutics

Several large investors have recently made changes to their positions in GALT. Solutions 4 Wealth Ltd purchased a new stake in shares of Galectin Therapeutics during the 4th quarter valued at $60,000. Retirement Guys Formula LLC increased its position in shares of Galectin Therapeutics by 56.9% during the 1st quarter. Retirement Guys Formula LLC now owns 33,732 shares of the company’s stock valued at $81,000 after purchasing an additional 12,232 shares during the last quarter. Wealthspire Advisors LLC increased its holdings in Galectin Therapeutics by 116.7% in the 1st quarter. Wealthspire Advisors LLC now owns 398,374 shares of the company’s stock worth $952,000 after acquiring an additional 214,512 shares during the last quarter. Vanguard Group Inc. increased its holdings in Galectin Therapeutics by 2.0% in the 1st quarter. Vanguard Group Inc. now owns 1,979,891 shares of the company’s stock worth $4,732,000 after acquiring an additional 38,037 shares during the last quarter. Finally, Traynor Capital Management Inc. increased its holdings in Galectin Therapeutics by 23.5% in the 2nd quarter. Traynor Capital Management Inc. now owns 42,871 shares of the company’s stock worth $97,000 after acquiring an additional 8,164 shares during the last quarter. 11.68% of the stock is owned by hedge funds and other institutional investors.

Galectin Therapeutics Company Profile

Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.